Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Working Capital Changes (2016 - 2025)

Karyopharm Therapeutics' Other Working Capital Changes history spans 14 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 8.59% year-over-year to $3.8 million; the TTM value through Dec 2025 reached -$438000.0, down 141.6%, while the annual FY2025 figure was $202864.0, 147.4% up from the prior year.
  • Other Working Capital Changes reached $3.8 million in Q4 2025 per KPTI's latest filing, up from -$223000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $26.2 million in Q4 2021 to a low of -$16.5 million in Q3 2022.
  • Average Other Working Capital Changes over 5 years is $1.5 million, with a median of -$740000.0 recorded in 2022.
  • The largest YoY upside for Other Working Capital Changes was 5352.53% in 2022 against a maximum downside of 1388.91% in 2022.
  • A 5-year view of Other Working Capital Changes shows it stood at $26.2 million in 2021, then crashed by 71.59% to $7.4 million in 2022, then tumbled by 63.14% to $2.7 million in 2023, then rose by 27.08% to $3.5 million in 2024, then increased by 8.59% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Other Working Capital Changes are $3.8 million (Q4 2025), -$223000.0 (Q3 2025), and -$2.0 million (Q2 2025).